Analyst thinks NewCardio set to rise Print E-mail
By Ray Dirks   
Thursday, 16 December 2010 01:43

penny stock profitsVeteran Research Analyst Ray Dirks has issued a recommendation for the common stock of NewCardio, Inc. (OTCBB:NWCI) at its current market price for very substantial capital appreciation over the near term. Dirks thinks that NewCardio will sell at $2.00 within one year and then at $5.00 or more within two years.

NewCardio is now commercializing its proprietary software product for automated ECG analysis used in cardiac safety clinical trials.  This product, which is known as QTinno, converts standard 12-lead ECG data into a virtual three-dimensional image of the heart that offers sensitivity and accuracy superior to traditional manual methods that are now in use. 

best penny stock picksThis process requires no change to existing ECG equipment or clinical practice.  NewCardio plans to leverage this 3-D technology over opportunities in ambulatory cardiac monitoring (CardioBip) and cardiac screening and diagnostics (Cardio3KG). NewCardio provides its software and support to established clinical trial service providers and study sponsors on a software as a service (SaaS) basis, which minimizes NewCardio’s infrastructure requirements and supports high software-type gross margins. NewCardio has completed master service agreements (MSAs) with 3 of the 5 largest CROs.

In the third quarter of 2010, NewCardio completed its first revenue-producing clinical trial, and then received an order for a second revenue-generating study.  CardioBip and Cardio3KG offer substantially larger long-term market opportunities than QTinno does.  The global market opportunity is more than $2 billion in CardioBip monitoring and over $1 billion for Cardio3KG in acute diagnosis of myocardial infarction.   

RAY DIRKS Research recommends NewCardio (OTCBB:NWCI) at $0.90

Price Target - -within One year:    $2.00
Price Target - - within Two year:      $5.00 +
Price Target - - within Three years:   $15.00

Revenues: 2010:     $500,000      (Estimate)
Revenues: 2011:    $4,000,000   (Estimate)
Revenues: 2012:     $12,000.000 (Estimate)
Estimated E.P.S.:  2010:   Loss of $0.30
Estimated E.P.S.:  2011:   Loss of $0.05
Estimated E.P.S.:  2012    $0.40

Shares Outstanding:  30 million
Market Capitalization:  $23 million

NewCardio has performed QTinno validation for 8 study sponsors including 2 top-20 pharmaceutical companies.  Management is preparing at least 6 studies for publication to support QTinno, CardioBip, and Cardio3KG.  We anticipate the announcement of favorable validation data during this current quarter (Q4, 2010) Numerous milestone announcements are likely in 2011 and 2012 including the strong probability of additional industry partners and substantial financing which can handle the exceptional growth opportunities.

Accordingly, we believe that NewCardio common stock has the capability of appreciating by 10 to 20 times over the next few years.       

Closer Look: NewCardio's exciting results

NWCI "Partnership/Buyout in the Works" After Company is Awarded Key Patent

Market drivers:

1.    High probability of a significant strategic relationship/investment to dramatically enhance companies marketing ability in its core business.  
2.    Potential strategic partner to execute commercialization of CardioBip.
3.    Established commercial relationships for QTinno™ with: GlaxoSmithKline, Quintiles, ICON, Dedicated Phase I
4.    Vinnie Renz as CEO – he was formerly executive at E-Research that took the company from $2 to $40 and was instrumental is sale of company.
5.    Near term revenues that should increate greatly in first quarter 2011
6.    Stock is highly undervalued.  They are far along and there is not much risk to commercialization.  

Disclosure:

The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.

The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.

The information on this Internet Site has been submitted by journalists and Analyst or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
  For more information, call Ray Dirks (1-917-923-0487) or e-mail to [email protected]





"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter